Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UTP11 small subunit processome component is an RNA-binding nucleolar protein involved in the biogenesis of the 18S ribosomal RNA by binding pre-rRNA processing factor MPP10. It is a critical component of the small subunit (SSU) processome, a ribosome assembly intermediate. UTP11 is overexpressed in diverse human cancers and correlates with poor prognosis. UTP11 depletion triggers nucleolar stress, which activates p53 signaling and arrests cancer cell growth. Additionally, UTP11 regulates NRF2-dependent ferroptosis, independent of p53, contributing to its role as an oncogenic protein. Targeting UTP11 may provide an attractive strategy for cancer therapy by inducing cell death through nucleolar stress and ferroptosis
- Induction of nucleolar stress leading to p53 activation and cancer cell growth arrest - Promotion of ferroptosis via destabilization of NRF2 mRNA and repression of SLC7A11 - Disruption of ribosome biogenesis (inhibiting 18S rRNA synthesis)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UTP11 small subunit processome component (UTP11).